Novonesis is a biosolutions company formed in 2024 through the combination of Novozymes and Chr. Hansen. It provides enzymes, microorganisms, and probiotics for industrial bioprocessing applications to optimize processes and increase production efficiency. The company operates through divisions supporting healthier lives and a healthier planet, serving the food and beverage, human health, and planetary health sectors. Its products include prebiotics, probiotics, enzymes, novel vitamins, and proteins, with notable brands such as BB-12™ and DVS®. Novonesis serves customers across more than 30 industries, including agriculture, dairy, laundry, and bioenergy. It has acquired MicroBioGen to strengthen yeast capabilities and dsm-firmenich’s animal feed enzyme business. The company traces its origins to the 1920s with the founding of Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium, which later merged into Novo Nordisk before Novozymes was spun off as an independent company.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Specialty Chemicals Homepage novonesis.com
Sector Basic Materials IR page novonesis.com/en/investors
Tags
biosolutions, enzymes, probiotics, microorganisms, industrial biotechnology, food ingredients, animal nutrition, bioenergy, fermentation, Novozymes, Chr. Hansen, Novonesis, BB-12™, DVS®, Alcalase, BioAg, MicroBioGen, dsm-firmenich, Feed Enzyme Alliance, Nordisk Insulinlaboratorium, Novo Terapeutisk Laboratorium, Novo Nordisk, Biosolutions Bulletin
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 5.3%
ROI 5.4%
ROIC 8.1%
Profit margin 14.0%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 5.7%
Quality  
Profitable Yes
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 53
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 4.158B 3.834B 2.4B 2.36B 2.011B
Net profit 583.6M 305.8M 405.55M 494.15M 423.1M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

As Indonesia develops its national bioeconomy strategy, a new report highlights how biosolutions could help unlock progress across some of the country's most important priorities, from food security and energy diversification to industrial transformation and its ambition to reach 8% economic growth by 2029.

CorporateCorporate & financial newsPress release3 Min readPublished on Oct. 28, 2026

VoB Indonesia launch

JAKARTA, Indonesia - October 28, 2026: As Indonesia lays the foundations for Golden Indonesia 2045, biosolutions could become a powerful driver of economic growth, job creation and industrial transformation, according to a new report.

Published as the government implements its National Long-Term Development Plan (RPJPN) 2025-2045 and BAPPENAS develops Indonesia's national bioeconomy roadmap, The Value of Biosolutions: Growth and Prosperity – Indonesia Edition highlights how Indonesia's abundant biological resources and ambitious development agenda could position the country as a future bioeconomy leader in Southeast Asia.

The report estimates that Indonesia's biosolutions sector could generate US$2.23 billion in economic value by 2035 while employment could nearly triple over the same period. That’s equivalent to more than twice the value of Indonesia's current coffee export, one of Indonesia's most celebrated agricultural commodities.

Every new biosolutions job is also expected to support another 3.8 jobs across the wider economy, with particularly strong effects in agriculture and food systems. This multiplier effect nearly 60% higher than the global average, underscoring how biosolutions, particularly in Indonesia, can strengthen local supply chains and create value far beyond the sector itself.

The findings suggest biosolutions could help accelerate progress across many of Indonesia's key development priorities, from food security, energy diversification and industrial transformation to job creation, investment, circularity and long-term resilience. The study also provides new evidence to support policy development and collaboration as Indonesia advances its bioeconomy ambitions.

"Biosolutions represent an important opportunity for Indonesia to harness its abundant biological resources in ways that support economic prosperity, environmental stewardship and national resilience," says Leonardo Adypurnama Alias Teguh Sambodo, Deputy for Food, Natural Resources, and Environmental Affairs at BAPPENAS. "As Indonesia advances its bioeconomy strategy, collaboration among government, industry, academia and development partners will be critical to unlocking this potential."

“Around the world, biosolutions are helping countries produce more with less, strengthen food and energy security, reduce emissions and build more resilient industries,” says Yonny Setiadi, Country Manager Indonesia, Novonesis. “Indonesia has the resources and ambitions to become a bioeconomy leader in Southeast Asia. This report shows how biosolutions, supported by the right policies, can accelerate growth, create high-quality jobs and advance the vision of Golden Indonesia 2045”.

The report also underscores the value of international collaboration and knowledge-sharing in supporting Indonesia's emerging bioeconomy. Denmark's experience offers insights that may prove valuable as Indonesia develops its national bioeconomy strategy:

"Denmark has seen how biological innovation can create real economic value. For decades, Danish companies and research institutions have developed technologies in enzymes, fermentation, and biotechnology that support industrial growth while contributing to our green transition. As Indonesia develops its national bioeconomy strategy, there is a valuable opportunity to bring these elements together and ensure that biosolutions are part of the country’s long-term economic development”, says Ambassador of Denmark to Indonesia H.E. Sten Frimodt Nielsen.

The Value of Biosolutions Report was launched today at BAPPENAS, where policymakers, industry leaders, researchers and development partners gathered to discuss the role biosolutions can play in advancing Indonesia's economic, industrial and sustainability ambitions. The event was co-hosted by BAPPENAS, Novonesis and the Embassy of Denmark in Indonesia.

Download the report: Indonesia Bioeconomy: USD 2.23B Biosolutions Opportunity

Media relations

Magnus Højberg Mernild

Magnus Højberg Mernild

Senior Media Relation Manager

[email protected] [+45 30 77 13 12](tel:+45 30 77 13 12)

Copyright © 2026 Novozymes A/S, part of Novonesis Group

Novonesis cookie preferences

Privacy preference center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information

Allow all

Manage consent preferences

Necessary Cookies

Always active

Necessary cookies enable smoother navigation through our websites. This is done by activating essential features like page transitions and access to secured areas of the website. The website would not be able to function optimally without these cookies, and therefore, this category of cookies cannot be disabled.

Cookies Details

Functional Cookies

Always active

Functional cookies are optional. They allow for personalization by storing information that changes the website's appearance or functions. For example, we may use these cookies to remember your language preferences or your geographical region.

Statistical Cookies

Always active

These cookies are optional and collect information about how you use our site in order for us to monitor and improve our site performance and services, and optimize your experience.

Cookies Details

Marketing Cookies

Always active

Marketing cookies are optional. They are used to collect cookies about your interests, including which websites and ads you click on, which products and services you are interested in, or purchase, on this and other websites or apps. We as well as third-party advertisers use this to personalise marketing both within our website, other websites, apps and on social media.

Cookies Details

Back Button

Cookie List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject all Confirm my choices

Powered by Onetrust

Major shareholder announcement Bull 0 Bear 0 Routine

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis has received a major shareholder notification from BlackRock, Inc. regarding its holdings in Novonesis.

As of October 21, 2026, BlackRock, Inc.’s aggregate holding of share capital amounts to 5.00% (previously 4.99%), comprising 4.99% of share capital attached to shares and 0.01% of share capital through financial instruments.

The full notification from BlackRock, Inc. is attached to this announcement.

Major shareholder announcement Bull 0 Bear 0 Routine

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis has received a major shareholder notification from BlackRock, Inc. regarding its holdings in Novonesis.

As of October 22, 2026, BlackRock, Inc.’s holding of share capital attached to shares amounts to 5.01% (previously 4.99%).

BlackRock, Inc.’s aggregate holding of share capital amounts to 5.02%, comprising 5.01% attached to shares and 0.01% through financial instruments.

The full notification from BlackRock, Inc. is attached to this announcement.

Prompts

Novonesis (Novozymes) (ticker NSIS-B), listed in Denmark.

ETFs Holding Novonesis (Novozymes)

ETF Weight in ETF Shares Market value As of
IGGY 1.18% 734 $ 52.741K Aug 31, 2026
SROI 0.44% 1,282 $ 83.463K Jul 31, 2026
DFIV 0.20% 684,884 $ 45.796M Nov 12, 2026
DFSI 0.12% 22,013 $ 1.472M Nov 12, 2026
TIER 0.12% 640 $ 41.679K Jul 31, 2026
NTSI 0.11% 8,651 $ 546.344K Jun 30, 2026
AVSD 0.10% 5,374 $ 355.451K Nov 16, 2026
DFIC 0.09% 200,283 $ 13.392M Nov 12, 2026
DFAI 0.08% 224,309 $ 14.999M Nov 12, 2026
DFAX 0.07% 124,202 $ 8.305M Nov 12, 2026
DXIV 0.06% 1,983 $ 132.598K Nov 12, 2026
AVDE 0.04% 129,236 $ 8.548M Nov 16, 2026